· Trials · Trials Desk
Once-daily oral VK2735 positions itself as the primary oral challenger to Lilly's orforglipron with a clean safety signal and locked-in manufacturing. NCT06828055.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.